Evidence map›Paper›PMID 35266589›Full record

ArticleAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2022

Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): A pilot randomized trial.

Daniel K Nishijima, John M VanBuren, Seth W Linakis, Hilary A Hewes, Sage R Myers, Nam K Tran, Simona Ghetti, Matthew Bobinski, P David Adelson, Ian Roberts and 6 more

Open access · greenAbstract read
In one paragraph

Article in Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Efficacy and Safety of Tranexamic Acid in Pediatric Trauma: A Systematic Review and Meta-Analysis.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
  2. Tranexamic Acid in Pediatric Care: A Comprehensive Overview.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 2 countries.

Daniel K NishijimaDepartment of Emergency Medicine, UC Davis School of Medicine, Sacramento, California, USA.ORCID https://orcid.org/0000-0003-4952-8212
John M VanBurenDepartment of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Seth W LinakisDepartment of Pediatrics, Division of Pediatric Emergency Medicine, Ohio State University School of Medicine, Nationwide Children's Hospital, Columbus, OH, USA.ORCID https://orcid.org/0000-0002-8527-2042
Hilary A HewesDepartment of Pediatrics, Division of Pediatric Emergency Medicine, University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, Utah, USA.
Sage R MyersDepartment of Pediatrics, Division of Pediatric Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nam K TranDepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, California, USA.ORCID https://orcid.org/0000-0003-1565-0025
Simona GhettiDepartment of Psychology, University of California, Davis, Davis, California, USA.
Matthew BobinskiDepartment of Radiology, UC Davis School of Medicine, Sacramento, California, USA.
P David AdelsonDepartment of Pediatric Neurosciences, Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona, USA.
Ian RobertsClinical Trials Unit, London School of Hygiene and Tropical Medicine, London, UK.
James F HolmesDepartment of Emergency Medicine, UC Davis School of Medicine, Sacramento, California, USA.ORCID https://orcid.org/0000-0003-3270-2720
Walton O SchalickDepartment of Orthopedics and Rehabilitation, University of Wisconsin, Madison, Wisconsin, USA.
J Michael DeanDepartment of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
T Charles CasperDepartment of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Nathan KuppermannDepartments of Emergency Medicine and Pediatrics, UC Davis School of Medicine, Sacramento, California, USA.
TIC‐TOC Collaborators of the Pediatric Emergency Care Applied Research Network (PECARN)
University of California, Davis · USUniversity of Utah · USUniversity of California Davis Medical Center · USBarrow Neurological Institute · USChildren's Hospital of Philadelphia · USNationwide Children's Hospital · USPrimary Children's Hospital · USUniversity of London · GBUniversity of Wisconsin–Madison · US

Funding

Utah Trial Innovation CenterU24TR001597 · NCATS · UNIVERSITY OF UTAH · PI DEAN, JONATHAN MICHAEL · 2016 to 2022
$39.6M
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC)R34HL135214 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KUPPERMANN, NATHAN, NISHIJIMA, DANIEL KIDEN · 2017 to 2018
$751k
HRSA HHSMaternal and Child Health Bureau U03MC00001Maternal and Child Health Bureau U03MC39944Medical Research Council MR/M009211/1NCATS NIH HHS L30 TR000286NCATS NIH HHS U24 TR001597NCATS NIH HHS U24TR001597NHLBI NIH HHS R34 HL135214NHLBI NIH HHS R34HL135214NIH HHSUniversity of CaliforniaUniversity of UtahU.S. Department of Health and Human Services
6 · The paper itself

Abstract

backgroundThe antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage; however, the drug has not been evaluated in a trial in injured children. We assessed the feasibility of a large-scale trial evaluating the effects of TXA in children with severe hemorrhagic injuries.

methodsSeverely injured children (0 up to 18th birthday) were randomized into a double-blind randomized trial of (1) TXA 15 mg/kg bolus dose, followed by 2 mg/kg/h infusion over 8 h, (2) TXA 30 mg/kg bolus dose, followed by 4 mg/kg/h infusion over 8 h, or (3) normal saline placebo bolus and infusion. The trial was conducted at four pediatric Level I trauma centers in the United States between June 2018 and March 2020. We enrolled patients under federal exception from informed consent (EFIC) procedures when parents were unable to provide informed consent. Feasibility outcomes included the rate of enrollment, adherence to intervention arms, and ability to measure the primary clinical outcome. Clinical outcomes included global functioning (primary), working memory, total amount of blood products transfused, intracranial hemorrhage progression, and adverse events. The target enrollment rate was at least 1.25 patients per site per month.

resultsA total of 31 patients were randomized with a mean age of 10.7 years (standard deviation [SD] 5.0 years) and 22 (71%) patients were male. The mean time from injury to randomization was 2.4 h (SD 0.6 h). Sixteen (52%) patients had isolated brain injuries and 15 (48%) patients had isolated torso injuries. The enrollment rate using EFIC was 1.34 patients per site per month. All eligible enrolled patients received study intervention (nine patients TXA 15 mg/kg bolus dose, 10 patients TXA 30 mg/kg bolus dose, and 12 patients placebo) and had the primary outcome measured. No statistically significant differences in any of the clinical outcomes were identified.

conclusionBased on enrollment rate, protocol adherence, and measurement of the primary outcome in this pilot trial, we confirmed the feasibility of conducting a large-scale, randomized trial evaluating the efficacy of TXA in severely injured children with hemorrhagic brain and/or torso injuries using EFIC.

Indexed as

clinical trialpediatric traumatranexamic acid

Identifiers

PMID35266589
PMCPMC9463410
OpenAlexW4220664702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.